Recent advances in the design and development of NNRTI scaffolds.

The non-nucleoside reverse transcriptase inhibitors have been always as important part of combination therapy called highly active antiretroviral therapy (HAART) since 1996. About twenty-two years usage of NNRTIs led to some mutations in reverse transcriptase active site amino acids and consequently emerging drug-resistance viruses. Thus, looking for novel potent NNRTIs with improved safety profile and activity against drug-resistant strains is indispensable and lots of hit and lead NNRTIs have been discovered in the last decade. This review tries to get an overview of recent development in this field from 2013 to 2018 (August).